Is the cost of anticancer therapy justified?
This article was originally published in Scrip
We all know that cardiovascular disease and cancer are the biggest causes of death in the developed world, but other types of disease impose a much greater overall burden of morbidity. For example, Datamonitor figures show that in the US in 2013 a total of 168.2 million patients were recorded with metabolic diseases such as diabetes, obesity, osteoporosis and lipid disorders, while 144.5 million patients were affected by CNS disorders that varied from migraine, depression, schizophrenia, and epilepsy to Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. In contrast, only 1.2 million cancer patients were recorded in the US in the whole of 2013. Cardiovascular disease came somewhere in between, with 85.1 million patients recorded with conditions such as hypertension, acute coronary syndrome, atrial fibrillation, myocardial infarction and stroke.
You may also be interested in...
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.